NCT06187103Active, not recruiting
Evaluation of Improved Onboard Patient Imaging
Evaluation of Improved Onboard Patient Imaging With the HyperSight Platform on TrueBeam 4.1
Source: ClinicalTrials.gov · Last updated 21 Apr 2026
Brief summary (registry, in English)
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any changes that may have occurred since the initial planning. Conventional CBCT technology is, however, limited by several factors including long acquisition times that result in motion artifacts in the image, smaller fields of view that limit the volume of anatomy that can be imaged, poor image quality that limits soft tissue visibility, and artifacts created by dense metal implants. This study will evaluate a novel CBCT imaging solution ("HyperSight") that has the potential to address the challenges of conventional CBCT.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 27 Nov 2023
- Start date
- 10 Jul 2024
- Primary completion date
- 5 Dec 2025
- Lead sponsor
- Varian, a Siemens Healthineers Company
- Diseases
- Head and neck cancer, Lung cancer
- NCT number
- NCT06187103
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 10 Jul 2024 to the primary completion date, 5 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient has known genetic pre-disposition for sensitivity to radiation (e.g., Li Fraumeni).
- Patient receives palliative radiation for 5 or fewer fractions.
Other
- Patient is pregnant or attempting pregnancy.
- Patient is part of a vulnerable population (per ISO 14155:2020, "individuals who are unable to fully understand all aspects of the investigation that are relevant to the decision to participate, or who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of retaliatory response"). This includes prisoners.
Who the study is looking for
- Patient is willing and able to provide written consent.
- Patient is at least 18 years of age at the time of consent.
- Patient has biopsy confirmed malignancy and recommendation for definitive or palliative radiation to the head and neck, breast, lungs, upper GI structures, or pelvis.
- Patient has ECOG performance status 0-2.
- Patient will be receiving radiation therapy at University of Maryland Medical Center, Department of Radiation Oncology.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Maryland Medical Center Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.